TrialHuman vaccines & immunotherapeutics2024

Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M

Vivek Shinde et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.